OSE Immunotherapeutics
OSE | PA
Overview
Corporate Details
- ISIN(s):
- FR0012127173 (+2 more)
- LEI:
- 969500HIUWVGY6NZSM05
- Country:
- France
- Address:
- 22 BOULEVARD BENONI GOULLIN, 44200 NANTES
- Sector:
- Health Care
- Industry:
- Biotechnology
Description
OSE Immunotherapeutics is an integrated biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology and autoimmune diseases. Based in Nantes (Head Office) and Paris, OSE Immunotherapeutics has 70 employees and is listed on Euronext Paris.
Financials & KPIs
No data available
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
Chat, Summarize & Extract with AI!
You have of free filing views remaining.
Upgrade for unlimited access.
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-05-23 07:00 |
Report Publication Announcement
OSE Immunotherapeutics annonce que son partenaire Boehringer Ingelheim présente…
|
French | 293.3 KB | |
| 2025-05-23 07:00 |
Regulatory News Service
OSE Immunotherapeutics Announces that its Partner Boehringer Ingelheim Will Pre…
|
English | 264.6 KB | |
| 2025-05-21 18:00 |
Regulatory News Service
OSE Immunotherapeutics annonce une collaboration stratégique sur des technologi…
|
French | 282.7 KB | |
| 2025-05-21 18:00 |
Regulatory News Service
OSE Immunotherapeutics Announces Strategic Collaboration to Pioneer Novel mRNA …
|
English | 319.0 KB | |
| 2025-05-06 18:00 |
Declaration of Voting Results & Voting Rights Announcements
Informations relatives au nombre total de droits de vote et d’actions composant…
|
French | 196.9 KB | |
| 2025-05-05 18:30 |
Earnings Release
OSE Immunotherapeutics Announces >90% of Responders Maintained Symptomatic Remi…
|
English | 282.0 KB | |
| 2025-05-05 18:30 |
Earnings Release
OSE Immunotherapeutics annonce que plus de 90% des patients répondeurs ont main…
|
French | 347.8 KB | |
| 2025-04-30 22:13 |
Annual Report (ESEF)
Document d'Enregistrement Universel 2024
|
French | 3.2 MB | |
| 2025-04-30 18:00 |
Regulatory News Service
Mise à disposition du Document d’Enregistrement Universel incluant le Rapport F…
|
French | 172.4 KB | |
| 2025-04-30 07:30 |
Regulatory News Service
Présentation des résultats d’une collaboration de recherche en Immuno-Oncologie…
|
French | 266.4 KB | |
| 2025-04-30 07:30 |
Regulatory News Service
Immuno-Oncology Results from Research Collaboration with Léon Bérard Cancer Cen…
|
English | 272.9 KB | |
| 2025-04-23 18:00 |
Regulatory News Service
OSE Immunotherapeutics Highlights Abstracts Selected for Presentation at ASCO …
|
French | 232.6 KB | |
| 2025-04-23 18:00 |
Regulatory News Service
OSE Immunotherapeutics annonce la sélection de plusieurs abstracts pour présent…
|
French | 232.6 KB | |
| 2025-04-09 07:30 |
Regulatory News Service
OSE Immunotherapeutics présentera des données inédites de la période d’extensio…
|
French | 194.1 KB | |
| 2025-04-09 07:30 |
Regulatory News Service
OSE Immunotherapeutics to Present Groundbreaking Extension Period Data on Lusve…
|
English | 177.9 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-06-19 | N/A | Other | Other | 10,000 | 35,700.00 EUR |
| 2024-06-17 | N/A | Other | Other | 10,000 | 35,800.00 EUR |
| 2024-06-17 | N/A | Other | Other | 10,000 | 35,700.00 EUR |
| 2024-06-13 | N/A | Other | Sell | 6,369 | 45,879.09 EUR |
| 2024-06-03 | N/A | Other | Sell | 40,000 | 314,512.00 EUR |
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
1NKEMIA | Spain | IKM | |
|
2cureX AB | Sweden | 2CUREX | |
|
4SC AG | Germany | VSC | |
|
Abera Bioscience AB | Sweden | ABERA | |
|
ABIONYX Pharma | France | ABNX | |
|
Abliva | Sweden | ABLI | |
|
AB Science | France | AB | |
|
Acticor Biotech | France | ALACT | |
|
Active Biotech | Sweden | ACTI | |
|
AcuCort AB | Sweden | ACUC |